
Erin Lynn Snelting
Examiner (ID: 5984, Phone: (571)272-7169 , Office: P/1741 )
| Most Active Art Unit | 1741 |
| Art Unit(s) | 1741, 1791 |
| Total Applications | 942 |
| Issued Applications | 609 |
| Pending Applications | 88 |
| Abandoned Applications | 271 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20497681
[patent_doc_number] => 20260027138
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-01-29
[patent_title] => PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT
[patent_app_type] => utility
[patent_app_number] => 19/347686
[patent_app_country] => US
[patent_app_date] => 2025-10-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4037
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19347686
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/347686 | PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT | Sep 30, 2025 | Pending |
Array
(
[id] => 20057305
[patent_doc_number] => 20250195527
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-19
[patent_title] => METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS
[patent_app_type] => utility
[patent_app_number] => 19/043303
[patent_app_country] => US
[patent_app_date] => 2025-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44330
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 80
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19043303
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/043303 | Methods for treating testicular and ovarian adrenal rest tumors | Jan 30, 2025 | Issued |
Array
(
[id] => 20039181
[patent_doc_number] => 20250177403
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-05
[patent_title] => METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS
[patent_app_type] => utility
[patent_app_number] => 19/043264
[patent_app_country] => US
[patent_app_date] => 2025-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44327
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19043264
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/043264 | Methods for treating testicular and ovarian adrenal rest tumors | Jan 30, 2025 | Issued |
Array
(
[id] => 20039182
[patent_doc_number] => 20250177404
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-05
[patent_title] => METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS
[patent_app_type] => utility
[patent_app_number] => 19/043275
[patent_app_country] => US
[patent_app_date] => 2025-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44333
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19043275
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/043275 | Methods for treating testicular and ovarian adrenal rest tumors | Jan 30, 2025 | Issued |
Array
(
[id] => 20024774
[patent_doc_number] => 20250162996
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-22
[patent_title] => AMINO ACID COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 19/030189
[patent_app_country] => US
[patent_app_date] => 2025-01-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8260
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19030189
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/030189 | AMINO ACID COMPOSITIONS | Jan 16, 2025 | Pending |
Array
(
[id] => 20024779
[patent_doc_number] => 20250163001
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-22
[patent_title] => AMINO ACID COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 19/030637
[patent_app_country] => US
[patent_app_date] => 2025-01-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8243
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19030637
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/030637 | Amino acid compositions | Jan 16, 2025 | Issued |
Array
(
[id] => 20024777
[patent_doc_number] => 20250162999
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-22
[patent_title] => AMINO ACID COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 19/030516
[patent_app_country] => US
[patent_app_date] => 2025-01-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7227
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19030516
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/030516 | Amino acid compositions | Jan 16, 2025 | Issued |
Array
(
[id] => 20024775
[patent_doc_number] => 20250162997
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-22
[patent_title] => AMINO ACID COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 19/030390
[patent_app_country] => US
[patent_app_date] => 2025-01-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7539
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 7
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19030390
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/030390 | Amino acid compositions | Jan 16, 2025 | Issued |
Array
(
[id] => 19845141
[patent_doc_number] => 20250090492
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-20
[patent_title] => Liquid Tasimelteon Formulations and Methods of Use Thereof
[patent_app_type] => utility
[patent_app_number] => 18/947694
[patent_app_country] => US
[patent_app_date] => 2024-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5552
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18947694
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/947694 | Liquid tasimelteon formulations and methods of use thereof | Nov 13, 2024 | Issued |
Array
(
[id] => 20239528
[patent_doc_number] => 12419831
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-23
[patent_title] => Hydrocortisone oral liquid formulations
[patent_app_type] => utility
[patent_app_number] => 18/932033
[patent_app_country] => US
[patent_app_date] => 2024-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42394
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 116
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18932033
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/932033 | Hydrocortisone oral liquid formulations | Oct 29, 2024 | Issued |
Array
(
[id] => 19743862
[patent_doc_number] => 20250032427
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-30
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING A STATIN AND A CANNABINOID AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/915730
[patent_app_country] => US
[patent_app_date] => 2024-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11000
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18915730
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/915730 | PHARMACEUTICAL COMPOSITIONS COMPRISING A STATIN AND A CANNABINOID AND USES THEREOF | Oct 14, 2024 | Pending |
Array
(
[id] => 19674484
[patent_doc_number] => 12186322
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-07
[patent_title] => Liquid oral formulations for tadalafil
[patent_app_type] => utility
[patent_app_number] => 18/665714
[patent_app_country] => US
[patent_app_date] => 2024-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16802
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18665714
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/665714 | Liquid oral formulations for tadalafil | May 15, 2024 | Issued |
Array
(
[id] => 19674483
[patent_doc_number] => 12186321
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-07
[patent_title] => Liquid oral formulations for sildenafil
[patent_app_type] => utility
[patent_app_number] => 18/626876
[patent_app_country] => US
[patent_app_date] => 2024-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16774
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18626876
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/626876 | Liquid oral formulations for sildenafil | Apr 3, 2024 | Issued |
Array
(
[id] => 19948327
[patent_doc_number] => 12319674
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-03
[patent_title] => Isatin derivatives
[patent_app_type] => utility
[patent_app_number] => 18/604704
[patent_app_country] => US
[patent_app_date] => 2024-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 0
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18604704
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/604704 | Isatin derivatives | Mar 13, 2024 | Issued |
Array
(
[id] => 19541598
[patent_doc_number] => 20240358634
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 18/603065
[patent_app_country] => US
[patent_app_date] => 2024-03-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 89467
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18603065
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/603065 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | Mar 11, 2024 | Pending |
Array
(
[id] => 19613066
[patent_doc_number] => 20240398746
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-05
[patent_title] => FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND EZETIMIBE AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/601088
[patent_app_country] => US
[patent_app_date] => 2024-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10862
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18601088
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/601088 | FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND EZETIMIBE AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE | Mar 10, 2024 | Pending |
Array
(
[id] => 19232079
[patent_doc_number] => 20240189270
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS
[patent_app_type] => utility
[patent_app_number] => 18/582125
[patent_app_country] => US
[patent_app_date] => 2024-02-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16245
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 146
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18582125
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/582125 | METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS | Feb 19, 2024 | Abandoned |
Array
(
[id] => 19279798
[patent_doc_number] => 20240216270
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-04
[patent_title] => HYDROCORTISONE ORAL LIQUID FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 18/443889
[patent_app_country] => US
[patent_app_date] => 2024-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49133
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18443889
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/443889 | Hydrocortisone oral liquid formulations | Feb 15, 2024 | Issued |
Array
(
[id] => 19246735
[patent_doc_number] => 20240197719
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => FORMULATIONS AND METHODS FOR THE PREVENTION OF OPIOID OVERDOSE
[patent_app_type] => utility
[patent_app_number] => 18/436976
[patent_app_country] => US
[patent_app_date] => 2024-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31856
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -68
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18436976
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/436976 | FORMULATIONS AND METHODS FOR THE PREVENTION OF OPIOID OVERDOSE | Feb 7, 2024 | Pending |
Array
(
[id] => 19512027
[patent_doc_number] => 20240343713
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-17
[patent_title] => TELOMERASE INHIBITOR COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 18/436936
[patent_app_country] => US
[patent_app_date] => 2024-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36567
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18436936
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/436936 | TELOMERASE INHIBITOR COMPOUNDS | Feb 7, 2024 | Pending |